Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

359 results about "DNA damage" patented technology

DNA damage is distinctly different from mutation, although both are types of error in DNA. DNA damage is an abnormal chemical structure in DNA, while a mutation is a change in the sequence of standard base pairs. DNA damages cause changes in the structure of the genetic material and prevents the replication mechanism from functioning and performing properly.

Application of PARPi sensitizer in treatment of malignant tumors

ActiveCN119185316AOrganic active ingredientsMicrobiological testing/measurementNon malignantSynthetic lethality
The invention provides application of a PARPi sensitizer in treatment of malignant tumors, and particularly relates to the technical field of biological medicines. A large number of experiments prove that TRMT10A is crucial for recruitment from BRCA1 to DNA damage sites for the first time, so that HR repair is promoted. The deletion of TRMT10A inhibits HR repair, so that tumor cells are more sensitive to PARPi. The invention discloses that the expression of TRMT10A in mCRPC is up-regulated, and the TRMT10A is regulated and controlled by ubiquitin specific peptidase 10 (USP10). Spautin-1 significantly results in the deficiency of TRMT10A, and sensitizes the tumor to PARPi in both patient-derived xenograft (PDX) and cell-derived xenograft (CDX). The research reveals that the ATM-TRMT10A-BRCA1 axis plays an important role in sensibilization of the PARP inhibitor, and a new angle is provided for exploring synthesis lethality. The mechanism can be therapeutically utilized through the combination of PARPi and Spautin-1, which may benefit more extensive patients with non-BRCA malignant tumors, and has important clinical significance.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Dual payload antibody drug conjugates

The present disclosure is related to dual payload antibody drug conjugates comprising at least one topoisomerase inhibitor and at least one DNA Damage Response (DDR) inhibitor, pharmaceutical compositions thereof, and the use of the antibody drug conjugates and compositions thereof for the treatment of diseases and disorders, including proliferative diseases.
Owner:SUTRO BIOPHARMA INC

Antibody-drug conjugates

An antigen-binding molecule that binds to a target antigen, comprising (i) a target antigen-binding moiety, and (ii) at least one linker-payload moiety, wherein the antigen-binding molecule comprises (a) DNA damage response (DDR) inhibitor moiety, and (b) a DNA topoisomerase I (TOP1) inhibitor moiety.
Owner:HUMMINGBIRD BIOSCIENCE HOLDINGS PTE LTD +1

Dynamic identification method for abnormal cells before young tumor based on multi-omics data

The invention discloses a dynamic identification method for unusual cells before young tumors based on multi-omics data, and relates to the technical field of cell unusual identification. A dynamic correlation intensity matrix and a cumulative effect contribution matrix are constructed, a differentiation screening strategy is implemented according to individual response characteristics, and the unusual cells before young tumors are identified. And the abnormal dynamic high-fidelity identification of the young tumor pre-cells is realized. And aiming at individuals of different response types, an instant path, a long-term path or a double-path fusion strategy is respectively adopted, key behavior data is accurately screened, and the input quality is improved. According to the method, redundant interference is effectively eliminated, the simulation capability of the model on key processes such as immunosuppression and DNA damage accumulation is enhanced, the biological rationality and prediction precision of a cell state evolution sequence are remarkably improved, and the problems of model response lag, low calculation efficiency and output distortion caused by data noise in the prior art are solved; and a reliable technical support is provided for early warning and individualized intervention of precancerous lesions.
Owner:SHENZHEN HOSPITAL CANCER HOSPITAL CHINESE ACAD OF MEDICAL SCI +1

Her2-binding molecules

An antigen-binding molecule that binds to HER2, comprising (i) a HER2-binding moiety, and (ii) at least one linker-payload moiety, wherein the antigen-binding molecule comprises (a) DNA damage response (DDR) inhibitor moiety, and (b) a DNA topoisomerase I (TOP1) inhibitor moiety.
Owner:HUMMINGBIRD BIOSCIENCE HOLDINGS PTE LTD +1

Biosynthesis method for preparing royal jelly acid and use thereof in skin care

PCT designated stage expiredWO2025040054A1Cosmetic preparationsFungiDecenoic AcidDNA damage
A biosynthesis method for preparing royal jelly acid and the use thereof in skin care, which belong to the technical field of genetic engineering and biosynthesis. The royal jelly acid is produced by means of fermentation on the basis of yeast engineering bacteria using a culture medium containing trans-2-decenoic acid. An assessment at both skin cell level and skin model level shows that royal jelly acid can promote the synthesis of stratum corneum lipids and ceramide on aging skin and repair the skin barrier; and also can promote the synthesis of mitochondria ATP and NADPH in skin fibroblasts, reduce the active oxygen content of mitochondria, improve mitochondrial dysfunctions, and inhibit apoptosis. Further experiments show that royal jelly acid can repair DNA damage of fibroblasts caused by ultraviolet irradiation, reduce telomere shortening caused by cell division and replication, and strengthen the protection of chromosomal terminal regions. The prepared royal jelly acid has wide application prospects in the development of functional skin care products for skin repairing, aging resisting, etc.
Owner:SHANDONG FREDA BIOTECH CO LTD

Polypeptide compound and application thereof

The invention provides a polypeptide compound and application thereof, and belongs to the technical field of medical or dressing preparations. According to the invention, three specific polypeptides are synergistically proportioned to obtain the polypeptide compound, and the polypeptide compound has the effect of repairing a skin basement membrane in a targeted manner. The polypeptide compound has the advantages of being small in molecular weight, high in safety, low in allergy risk and high in permeability, and has excellent repairing and anti-aging functions. Experiments prove that the polypeptide compound provided by the invention, as an active peptide raw material, can remarkably promote the production of endogenous collagen IV, VII and XVII of skin, is also beneficial to repairing skin extracellular matrix, resisting DNA damage, improving skin cycle protein, inhibiting release of inflammatory factors and the like, can effectively repair a basement membrane, and has a wide application prospect.
Owner:苏州拾光医药生物科技有限公司 +2

An anti-aging composition, anti-aging cosmetic, and preparation method and application thereof

The present invention discloses an anti-aging composition, an anti-aging cosmetic and its preparation method and application. The anti-aging composition includes torreya grandis oil, hydrolyzed Brazil nut protein, angoloside C, carnosic acid and nanovesicle excipients. The present invention uses the above four natural plant components as anti-aging active ingredients, and from multiple perspectives such as promoting collagen synthesis, inhibiting the expression of inflammatory factors, scavenging free radicals, and repairing DNA damage, it exerts a significant anti-aging effect. The present invention encapsulates the above anti-aging active ingredients in the form of nanovesicles, which not only improves the stability of the active ingredients, but also improves the skin absorption effect of the active ingredients. The liposome nanovesicles have good compatibility with the matrix of the cosmetic, effectively solving the compatibility problem between the active ingredients and the cosmetic matrix.
Owner:BEIJING MEMBRANA BIOTECHNOLOGY CO LTD

Methods of treating cancer with long-acting topoisomerase i inhibitor

The disclosure provides method of treating cancer in a patient in need thereof, comprising safely and efficaciously administering to the patient PLX038, a long lasting-PEGylated prodrug of the topoisomerase I inhibitor. The disclosure further provides combination therapies of PLX038 with inhibitors of the DNA damage response (DDR).
Owner:PROLYNX LLC

Traditional Chinese medicine composition for repairing and / or activating residual ovarian function of senescence ovary and preparation method and application thereof

The invention discloses a traditional Chinese medicine composition for repairing and / or activating residual ovarian functions of an aging ovary, and a preparation method and application thereof, and relates to the technical field of biology. The traditional Chinese medicine composition is prepared from the following components: radix astragali, radix angelicae sinensis, radix ophiopogonis, radix polygonati officinalis, semen cuscutae, radix morindae officinalis, fructus rubi, rhizoma dioscoreae and folium mori. The invention further provides application of the traditional Chinese medicine composition in repairing and / or activating the residual ovarian function of the senescent ovary and improving the quality of the senescent oocyte, the traditional Chinese medicine composition can increase the volume and weight of the senescent ovary, increase the number of follicles of all levels in the senescent ovary, reduce apoptosis of granular cells in the ovary and improve the survival rate of the senescent ovary. The abnormal rate of oocytes, oxidative stress of the oocytes and DNA damage are reduced, development and maturation of residual follicles are promoted and maintained, and the traditional Chinese medicine composition has a wide application prospect.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE

NTSR1-targeted radiopharmaceuticals and DNA damage response inhibitor combination therapy

Methods for treating or ameliorating cancer comprising administering to a mammal a NTSR-1 targeted radiopharmaceutical comprising a radionuclide chelated to a compound of formula I, and DNA damage response inhibitors.
Owner:3B PHARM GMBH

Neural cell senescence resisting medicine containing p-hydroxybenzaldehyde and application of nerve cell senescence resisting medicine

The invention discloses a nerve cell senescence resisting medicine containing p-hydroxybenzaldehyde and application thereof.The p-hydroxybenzaldehyde is adopted as the only active substance, and the p-hydroxybenzaldehyde can reduce accumulation of DNA damage in cells, reduce activity of beta-galactosidase in the cells and slow down reduction of cell metabolic capacity, so that the nerve cell senescence resisting medicine is obtained. Therefore, the senescence of nerve cells is effectively slowed down, the cognitive function is improved, and a potential treatment effect is achieved in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
Owner:UNIV OF MACAU

Dual-targeting macrophage membrane nano system as well as preparation method and application thereof

The invention discloses a dual-targeting macrophage membrane nano system and a preparation method and application thereof, and belongs to the field of biological medicine, MKA is wrapped in a macrophage membrane after AuNPs and mitochondrial targeting peptide KLA are connected. The preparation method comprises the following steps: firstly synthesizing AuNPs and modifying, and then wrapping with a macrophage membrane. In treatment, the compound can realize double targeting of tumor cells and mitochondria, enhance radiation-induced DNA damage, inhibit DDR, activate immune pathways and promote T cell infiltration, and can also consume glutathione and amplify oxidative stress to enhance immune effect, and the dose enhancement ratio of the compound in cooperation with 8GyX-rays reaches 3.1. In addition, the MKA is good in biocompatibility in vivo, long in blood circulation time, high in tumor targeting and capable of being quickly cleared through the kidney. The invention provides a new way for tumor radioimmunotherapy, and is helpful for promoting the progress of clinical tumor treatment.
Owner:ANHUI PROVINCIAL HOSPITAL

Treating cancer with long-acting topoisomerase i inhibitor

The disclosure provides method of treating cancer in a patient with ATM-deficient or ATR-deficient tumors, comprising safely and efficaciously administering to the patient PLXO38, a long lasting-PEGylated prodrug of the topoisomerase I inhibitor. The disclosure further provides combination therapies of PLXO38 with inhibitors of the DNA damage response (DDR).
Owner:PROLYNX LLC

Efficient identification of new small molecules targeting succinate dehydrogenase

Efficient lung cancer treatment is challenging due to the lack of therapeutic targets. The succinate dehydrogenase (SDH) enzyme plays a critical metabolic role as an intermediate between the citric acid cycle and the electron transport chain associated with the cancer disease state. Although several existing compounds have been applied to target metabolic diseases in vitro, modulating SDH for lung cancer treatment has been elusive. By integrating the AtomNet® technology for compound identification with mitochondria- and cell-based enzyme activity assays, this disclosure demonstrates identification of four new small molecules that bind directly to SDH subunits in lung cancer cells. Mechanistically, treatment with these small molecules increased reactive oxygen species and DNA damage in lung cancer cell lines. Functionally, these small molecules reduced short-term and long-term malignant growth of lung cancer cell lines in vitro. This study provides a new therapeutic approach for targeting lung and other types of cancers through modulation of SDH.
Owner:UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION INC

Application of red rice extract, red rice extract and preparation method of red rice extract

The invention provides application of a red rice extract, the red rice extract and a preparation method of the red rice extract. The red rice extract has the application of promoting heat shock protein expression, repairing DNA damage, reducing sunburn cells, resisting cell senescence and inhibiting inflammation, and can be used for preparing medicines, cosmetics or health care products. The preparation method of the red rice extract comprises the following steps: extracting red rice with an aqueous solution of dihydric alcohol, and carrying out solid-liquid separation to obtain supernate, namely the red rice extract.
Owner:BETTER WAY (SHANGHAI) COSMETICS CO LTD

Composition for improving permeation effect of bark extract of Campanumoea maculata and preparation method and application of composition

The invention provides a composition for improving the permeation effect of a Campania maculata bark extract as well as a preparation method and application of the composition, and relates to the technical field of cosmetics. The invention provides an anti-aging composition for improving the permeation effect of a Campandra maculata bark extract. The anti-aging composition comprises recombinant human III type collagen, the Campandra maculata bark extract, an annona squamosa fruit extract, a Flos Magnoliae extract and a film-forming agent, the film-forming agent is composed of rhamnose and a trimethyl pentanediol / adipic acid / glycerol cross-linked polymer. The combination of the recombinant human III type collagen and the film-forming agent can strengthen hydration of cuticle, optimize the controlled release efficiency of active ingredients and broaden the permeation path, thereby forming an efficient permeation network from the skin surface to the deep layer. The combination of the Campandra mollissima bark extract, the Annona mollissima fruit extract and the Flos Magnoliae extract can construct a multi-dimensional antioxidant network, activate longevity proteins to resist saccharification and DNA damage, and comprehensively delay skin aging.
Owner:INERTIA SHANGHAI BIOTECHNOLOGY CO LTD +1

Asparagine endopeptidase inhibitor neuronal targeting liposome and preparation method thereof

The invention relates to an asparagine endopeptidase inhibitor neuronal targeting liposome and a preparation method thereof. The liposome comprises the following components: lecithin, cholesterol, phospholipid polyethylene glycol polypeptide, a fluorescent dye and an asparagine endopeptidase inhibitor. The preparation method has relatively good drug loading capacity and entrapment efficiency; after being atomized and dosed through a nose, the nebulizer can smoothly enter the brain of a mouse through a blood brain barrier to be distributed, and has good biocompatibility; according to the invention, DNA damage and ROS reaction of irradiated brain neurons and glial cells can be reduced, and the research and development value and important academic significance of the liposome for assisting in improving radiation brain injury are revealed.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Setdb1 inhibitor for use in the treatment of uveal melanoma

Metastatic uveal melanomas are highly resistant to all existing treatments. To identify actionable vulnerabilities, the inventors conducted a CRISPR-Cas9 knockout screen using a library composed of chromatin remodelers. They revealed that the histone H3 methyltransferase SETDB1 plays a critical role in metastatic uveal melanoma cell proliferation and survival. Functionally, SETDB1 knockdown triggers decreased expression of genes related to replication and cell cycle and promotes growth arrest associated with increased markers for DNA damage and senescence entry. Using pre-clinical model, they further demonstrated that anti-SETDB1 therapy tumor growth in vivo. The inventors identify SETDB1 as a new relevant therapeutic target for the treatment of metastatic uveal melanomas. The present invention relates to a method for treating uveal melanoma in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of SETDB1 inhibitor.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1

Application of STAT1 / 3 inhibitor in preparation of medicine for improving cis-platinum drug resistance

The invention provides an application of an STAT1 / 3 inhibitor in preparation of a medicine for improving cis-platinum drug resistance, and an application of nifurazil and cis-platinum as STAT1 / 3 inhibitors in preparation of a combined medicine for treating tumors with cis-platinum drug resistance. The key DNA damage response protein for regulating and controlling the non-small cell lung cancer cell cis-platinum drug resistance is designed and determined, the key small molecule inhibitor nifurazil for enhancing the drug effect of cis-platinum on drug-resistant cells is screened out, the nifurazil is combined with cis-platinum to be used for treating cis-platinum drug-resistant tumors, the synergistic interaction effect is achieved, and the application prospect is wide. A new thought is provided for overcoming the tumor drug resistance.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Application of receptor helper protein 6 and inhibitor thereof in preparation of medicine for treating oral squamous cell carcinoma

The invention discloses a receptor helper protein 6 and application of an inhibitor thereof in preparation of a medicine for treating oral squamous cell carcinoma. The invention discloses a receptor helper protein 6 as a novel ferroptosis inhibiting factor in OSCC cells, which is a key protein in a ferroptosis signal pathway and can be used as a drug target for overcoming the progress of oral squamous cell carcinoma. The knock-down of the REEP6 significantly inhibits the cell reproduction rate in the OSCC cell line, significantly promotes DNA damage in the OSCC cell line and significantly inhibits migration and invasion of the OSCC cell line, so that the inhibitor of the targeted receptor helper protein 6 can be applied as a drug for treating oral squamous cell carcinoma. The invention provides a new thought for diagnosing and preparing medicines for treating oral squamous cell carcinoma.
Owner:TAIHE HOSPITAL OF SHIYAN CITY (AFFILIATED HOSPITAL OF HUBEI UNIVERSITY OF MEDECINE)

MeDIP-MSRE-based whole genome methylation detection method

The invention discloses a whole genome methylation detection method based on MeDIP-MSRE, and belongs to the technical field of epigenetics detection. According to the method, methylation immunoprecipitation sequencing and a methylation sensitive restriction enzyme technology are innovatively combined, firstly, a methylation specific antibody is used for conducting immunoprecipitation on sample DNA, and whole genome methylation fragments are enriched; then carrying out enzyme digestion on the enriched product by adopting methylation sensitive restriction enzyme, specifically removing an unmethylated DNA region, and reserving a complete methylation sequence; and finally, constructing a methylation map through high-throughput sequencing. According to the method, traditional hydrosulfite chemical conversion is not needed, DNA damage and base conversion deviation caused by the traditional hydrosulfite chemical conversion are avoided, meanwhile, high sensitivity of MeDIP and high specificity of methylation sensitive restriction endonuclease are fused, and the fidelity, sensitivity and specificity of detection are remarkably improved.
Owner:ZHONGKE JINCHEN BIOTECHNOLOGY (HEFEI) CO LTD

A Composition and A Method of Rejuvenating DNA and Preventing DNA Damage

The present disclosure relates to a method for rejuvenating DNA and / or preventing DNA damage within a nucleus of a cell. The method generally comprises administering a reagent having a vector containing a polynucleotide sequence as setting forth in SEQ ID No. I or SEQ ID No. 2 encoding for a peptide into the cell, the vector being configured to express the encoded peptide within the cell; and overexpressing the encoding encoded peptides, wherein the overexpressed peptides form one or more complexes, within the cell, capable of rejuvenating DNA and preventing damage of DNA in the nucleus of the cell.
Owner:CHULALONGKORN UNIVERSITY

Whitening, anti-wrinkle, firming and soothing multi-effect composition and application thereof

The invention discloses a whitening, anti-wrinkle, firming and soothing multi-effect composition, which is prepared from the following raw material components: nicotinamide, hydroxypropyl tetrahydropyrantriol, p-hydroxyacetophenone, glycerol, 1, 2-pentanediol, 1, 2-hexanediol, a barley extract composition, panthenol, a radix gentianae extract composition, an oat kernel extract composition and the balance of water. The barley extract, the radix gentianae extract and the oat kernel extract are added into the whitening, anti-wrinkle, firming and soothing multi-effect composition, so that melanosome can be inhibited from being transferred to the skin surface, DNA damage caused by UV is repaired, photoimmunosuppression is intervened, elastase and hyaluronidase are inhibited, and the whitening, anti-wrinkle, firming and soothing multi-effect composition has the advantages that the whitening, anti-wrinkle, firming and soothing functions are realized; the face cream prepared from the multi-effect composition for whitening, resisting wrinkles, tightening and relieving has the effects of whitening, resisting wrinkles, tightening and relieving.
Owner:AUSMETICS DAILY CHEM (GUANGZHOU) CO LTD

Application of cucurbitacine I in preparation of cisplatin sensitizing drug for treating ovarian cancer

The invention discloses application of cucurbitacine I in preparation of cisplatin sensitization drugs for treating ovarian cancer, and belongs to the technical field of sensitization drugs for tumor chemotherapy. CuI and CDDP have a good synergistic tumor inhibition effect on ovarian cancer, CuI may directly act on EGFR and can be combined with CDDP to significantly inhibit phosphorylation of EGFR and downstream STAT3 protein thereof, induce DNA damage and ROS accumulation, amplify a pyroptosis effect, increase release of TAAs and DAMPs, promote DC maturation and promote infiltration of CD8 + T cells and memory T cells in TIME in vivo, so that the tumor inhibition effect on ovarian cancer is improved. The expression of an inhibitory costimulatory molecule PD-1 in CD8 + T cells is reduced, the whole body immune effect is activated, and the TIME of the ovarian cancer is remarkably improved. The combined treatment strategy of CuI-CDDP controls the progress of ovarian cancer from a dual mechanism of directly inhibiting tumor cells and promoting anti-tumor immune activation.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Application of PDLIM4 inhibitor in preparation of medicine for regulating and controlling sensitivity of gastric cancer to cis-platinum

The invention relates to the technical field of biological medicine, and provides application of a PDLIM4 inhibitor in preparation of a medicine for regulating and controlling sensitivity of gastric cancer to cis-platinum. According to the present invention, the PDLIM4 inhibitor is applied to the preparation of the drug for regulating the sensitivity of the gastric cancer cells to the cis-platinum, and the expression of the PDLIM4 in the gastric cancer cells is inhibited so as to reduce the expression of the HSP70 and promote the DNA damage signal channel, such that the sensitivity of the gastric cancer cells to the cis-platinum is enhanced;
Owner:南昌大学第一附属医院

Application of a cerium monatomic functional material in preparation of a tumor radiotherapy sensitizer

PendingCN122376737APeroxidaseApoptosis
The application discloses application of a cerium monatomic functional material in preparation of a tumor radiotherapy sensitizer. SA In the material, cerium is dispersed on a nitrogen-doped carbon carrier in a monatomic form and forms a stable coordination structure with N / O. The application determines the structure-activity relationship of the unique physical and chemical structure and multiple enzyme activities, verifies the radiotherapy sensitization effect and biological safety in and out of the body. The material has multiple enzyme activities such as simulating peroxidase and glutathione oxidase, can efficiently catalyze ROS and consume GSH, and enhances DNA damage and apoptosis induced by ionizing radiation. In vitro clone formation experiments show that the radiotherapy sensitization ratio reaches 1.38, which is better than that of CeO2 nano clusters (1.17). In vivo experiments on tumor-bearing mice prove that the material combined with radiotherapy can significantly inhibit tumor growth, prolong survival time, and has good biocompatibility. The application provides a new strategy of high efficiency and low toxicity for tumor radiotherapy sensitization, and has a good clinical application prospect.
Owner:ANHUI MEDICAL UNIV

Cancer treatment medicine composition and application thereof in preparation of esophageal cancer treatment medicine

The invention relates to the field of biological medicine, in particular to a cancer treatment medicine composition and application thereof in preparation of esophageal cancer treatment medicine. The purpose of the present invention is to provide a cancer treatment pharmaceutical composition, which comprises a therapeutically effective amount of an inhibition component, and the inhibition component is used for inhibiting the expression of ALKBH3. The pharmaceutical composition provided by the invention can effectively inhibit the expression level of the ALKBH3 gene, has an inhibiting effect on growth, proliferation and migration of esophageal cancer cells, and can also induce esophageal cancer cell DNA damage and increase the sensitivity of tumor cells to radiotherapy and chemotherapy.
Owner:ZHEJIANG PROVINCIAL PEOPLES HOSPITAL